News
Recent FDA updates in the areas of cardiac intervention, hypertension and arrhythmia disorders expand the pool of available ...
CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Gearing Up for Phase 3 Trial of Tecarfarin Cadrenal Therapeutics, Inc ...
Advances in heart failure treatment have reduced hospitalizations by up to 30% and extended lives by years. Learn about ...
The HeartMate II is currently the only continuous-flow left-ventricular assist device (LVAD) approved by the FDA for both bridge-to-transplantation and destination therapy. Because of its ...
AI tools are effective for detecting left ventricular systolic dysfunction among women of reproductive age seen in primary care.
"Now, the WiSE System brings a leadless solution to left ventricular pacing ... The WiSE System syncs with existing pacing devices—pacemakers, ICDs, or CRTs—using a subcutaneous ultrasound ...
Health Check: With the FDA’s approval, EBR is ready to revolutionise the heart failure device market
The US Food & Drug Administration has approved EBR System’s leadless pacemaker WISE, the only device able to deliver left-ventricle stimulation. Ecstatic CEO John McCutcheon said the FDA's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback